Los Angeles Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Los Angeles Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.3K	Hold	103	–	–	﹤0.01%	2326
2025 Q4	$1.12K	Buy	+103	New	+$1.31K	﹤0.01%	2474
2021 Q2	–	Sell	-4,810	Closed	-$237K	–	1573
2021 Q1	$237K	Sell	4,810 -10,545	-69%	-$526K	﹤0.01%	1497
2020 Q4	$646K	Sell	15,355 -1,925	-11%	-$84.7K	﹤0.01%	1104
2020 Q3	$791K	Hold	17,280	–	–	﹤0.01%	911
2020 Q2	$868K	Sell	17,280 -125	-0.7%	-$6.47K	﹤0.01%	902
2020 Q1	$895K	Sell	17,405 -18,125	-51%	-$966K	0.01%	737
2019 Q4	$2.19M	Sell	35,530 -15,212	-30%	-$943K	0.01%	624
2019 Q3	$3.05M	Sell	50,742 -18,360	-27%	-$1.36M	0.02%	525
2019 Q2	$5.83M	Buy	69,102 +63,742	+1,189%	+$5.73M	0.03%	412
2019 Q1	$512K	Buy	5,360 +1,070	+25%	+$96K	﹤0.01%	1072
2018 Q4	$304K	Buy	4,290 +650	+18%	+$49.8K	﹤0.01%	1095
2018 Q3	$311K	Buy	+3,640	New	+$365K	﹤0.01%	1214

Other funds holding ENTA

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SSC

Spruce Street Capital New York $416M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Los Angeles Capital Management's ENTA Position: Q1 2026 in Review

Los Angeles Capital Management held its Enanta Pharmaceuticals (ENTA) position steady in Q1 2026 at 103 shares worth $1.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2326.

Los Angeles Capital Management first reported a position in ENTA in Q3 2018 and has held it in 13 quarters since. The position peaked at $5.83M in Q2 2019. 132 funds tracked by Wall St. Rank hold ENTA as of Q1 2026.

Los Angeles Capital Management held 103 shares of Enanta Pharmaceuticals worth $1.3K as of Q1 2026.
Los Angeles Capital Management left its Enanta Pharmaceuticals share count unchanged in Q1 2026.
Enanta Pharmaceuticals made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #2326 holding.
Los Angeles Capital Management first reported a position in Enanta Pharmaceuticals in Q3 2018 and has held it in 13 quarters since.
Los Angeles Capital Management's Enanta Pharmaceuticals position peaked at $5.83M in Q2 2019.
132 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.